Sonja Gill
Director, Oncology Safety Combinations, Clinical Pharmacology & Safety Sciences AstraZeneca
Seminars
Thursday 3rd December 2026
Insight Exchange – Can We Ever Reliably Predict Safety & Efficacy Before the Clinic?
11:50 am
- Which endpoints remain hardest to predict with current models?
- How should teams balance efficacy and safety when selecting models?
- What breakthroughs are needed to improve prediction of clinical outcomes?
- Audience Q&As
Thursday 3rd December 2026
Evidence – Human-Relevant Safety NAMs for Translational Confidence & Therapeutic Index in Oncology Drug Development
10:40 am
- Human-relevant target organ NAMS can improve translation beyond traditional in vivo models, enabling more predictive assessment of specific safety risks
- A bone marrow MPS enables assessment of drug-induced marrow suppression for oncology monotherapies and combination therapies
- Bone marrow MPS integrated with quantitative systems toxicology modelling supports reliable prediction of patient hematologic effects for oncology therapeutics
